COMPARISON OF GLYCEMIC AND METABOLIC PARAMETERS BETWEEN TYPE 2 DIABETES MELLITUS PATIENTS AND HEALTHY CONTROLS IN KASHMIR: A CASE-CONTROL STUDY
Main Article Content
Keywords
Type 2 diabetes mellitus, insulin resistance, dyslipidemia, hyperuricemia, Kashmir.
Abstract
Type 2 diabetes mellitus (T2DM) is frequently associated with multiple metabolic derangements including insulin resistance, dyslipidemia, and hyperuricemia, which significantly elevate the risk of cardiovascular and renal complications. This study aimed to evaluate and compare glycemic, anthropometric, and metabolic parameters between T2DM patients and healthy controls in the Kashmiri population and to identify predictors of hyperuricemia among diabetic individuals.
Methods:
A total of 298 diagnosed T2DM patients and 310 age- and sex-matched healthy controls were enrolled. Anthropometric indices (BMI, waist circumference), fasting glucose, HbA1c, fasting insulin, HOMA-IR, lipid profile, and serum uric acid were measured. Multivariate logistic regression was used to identify predictors of hyperuricemia in T2DM.
Results:
T2DM patients had significantly higher BMI, waist circumference, fasting glucose, HbA1c, insulin levels, HOMA-IR, triglycerides, LDL-C, and serum uric acid, and lower HDL-C compared to controls (p < 0.001). Coexisting dyslipidemia and hyperuricemia were observed in 34.8% of T2DM patients. BMI ≥ 27 kg/m² (OR 1.84), HOMA-IR ≥ 5 (OR 2.03), and triglycerides ≥ 150 mg/dL (OR 1.77) were independent predictors of hyperuricemia. Poor glycemic control (HbA1c ≥ 7%) was significantly associated with increased prevalence of both dyslipidemia and hyperuricemia.
Conclusion:
T2DM patients in Kashmir exhibit significant insulin resistance and concurrent metabolic disturbances. Hyperuricemia is strongly associated with obesity, insulin resistance, and dyslipidemia. Integrated glycemic and metabolic management strategies are essential to mitigate long-term complications in this population.
References
2. Taskinen MR. Diabetic dyslipidemia. Atheroscler Suppl. 2002 May;3(1):47-51.
3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov;157:107843.
4. Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Sci Rep. 2024 Mar 22;7(3):e2004.
5. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018 Jun 8;17(1):83.
6. Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015 Oct 10;6(13):1246-58.
7. Mandal AK, Hiebert L. Diagnosis and management of diabetes and the relationship of dglucose to kidney function. Curr Diabetes Rev. 2015;11(2):116-21.
8. Bashir H, Majid S, Khan MS, Bhat MH, Hamid R, Ashraf R, Faiz S. Inter-relationship of Pro- and Anti- inflammatory Biomarkers with the development of Type 2 Diabetes Mellitus. Heliyon. 2022 Oct 31;8(11):e11329.
9. Bashir H, Ahmad Bhat S, Majid S, Hamid R, Koul RK, Rehman MU, Din I, Ahmad Bhat J, Qadir J, Masood A. Role of inflammatory mediators (TNF-α, IL-6, CRP), biochemical and hematological parameters in type 2 diabetes mellitus patients of Kashmir, India. Med J Islam Repub Iran. 2020 Feb 12;34:5.
10. Bhat JA, Majid S, Tripathi H, Tanveer M, Bhat SA, Bashir H, Qadir J. Study on central obesity in newly diagnosed diabetes mellitus patients of Kashmir valley: a prospective study. J Adv Med Dent Scie Res 2020;8(6): 188-191.
11. Hasheminasabgorji E, Jha JC. Dyslipidemia, Diabetes and Atherosclerosis: Role of Inflammation and ROS-Redox-Sensitive Factors. Biomedicines. 2021 Nov 3;9(11):1602.
12. Bjornstad P, Laffel L, Lynch J, El Ghormli L, Weinstock RS, Tollefsen SE, Nadeau KJ; TODAY Study Group. Elevated Serum Uric Acid Is Associated With Greater Risk for Hypertension and Diabetic Kidney Diseases in Obese Adolescents With Type 2 Diabetes: An Observational Analysis From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. Diabetes Care. 2019 Jun;42(6):1120-1128.
13. Ma L, Wang J, Ma L, Wang XM. The link between hyperuricemia and diabetes: insights from a quantitative analysis of scientific literature. Front Endocrinol (Lausanne). 2025 Feb 7;15:1441503.
14. Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, Pang Y, Zhang C, Zhong Z, Gao J. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024 Aug 28;9(1):212.
15. Rathod L, Khan S, Mishra S, Das D, Bora K, Shubham S, Singh S, Kumar M, Tiwari RR, Tiwari A, Mishra PK, Sarma DK. Genetic variants and type 2 diabetes in India: a systematic review and meta-analysis of associated polymorphisms in case-control studies. Lancet Reg Health Southeast Asia. 2024 Dec 10;32:100518.
16. Lone SS, Majid S, Bhat MH, Wani GA. Exploring the burden of mixed dyslipidemia in patients with type 2 diabetes mellitus: A cross-sectional study in Kashmir, India. Am J Hum Biol. 2024 Apr;36(4):e24012.
17. Deji-Oloruntoba, Opeyemi. O., James Onoruoiza Balogun, Taiwo. O. Elufioye, and Simeon Okechukwu Ajakwe. 2025. "Hyperuricemia and Insulin Resistance: Interplay and Potential for Targeted Therapies" International Journal of Translational Medicine 5, no. 3: 30.
18. Soltani Z, Rasheed K, Kapusta DR, Reisin E. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep. 2013 Jun;15(3):175-81.
19. American Diabetes Association; Standards of Medical Care in Diabetes—2018 Abridged for Primary Care Providers. Clin Diabetes 1 January 2018; 36 (1): 14–37.
20. Paniagua JA. Nutrition, insulin resistance and dysfunctional adipose tissue determine the different components of metabolic syndrome. World J Diabetes. 2016 Nov 15;7(19):483-514.
21. Kosmas CE, Bousvarou MD, Kostara CE, Papakonstantinou EJ, Salamou E, Guzman E. Insulin resistance and cardiovascular disease. J Int Med Res. 2023 Mar;51(3):3000605231164548.
22. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018 May;34(5):575-584.
23. Lee J, Kim MH, Jang JY, Oh CM. Assessment HOMA as a predictor for new onset diabetes mellitus and diabetic complications in non-diabetic adults: a KoGES prospective cohort study. Clin Diabetes Endocrinol. 2023 Nov 16;9(1):7.
24. Mansoori A, Tanbakuchi D, Fallahi Z, Rezae FA, Vahabzadeh R, Soflaei SS, Sahebi R, Hashemzadeh F, Nikravesh S, Rajabalizadeh F, Ferns G, Esmaily H, Ghayour-Mobarhan M. Uric acid is associated with type 2 diabetes: data mining approaches. Diabetol Int. 2024 Apr 16;15(3):518-527.
25. Hirano T. Pathophysiology of Diabetic Dyslipidemia. J Atheroscler Thromb. 2018 Sep 1;25(9):771-782.
26. Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian J Endocrinol Metab. 2016 Jul-Aug;20(4):546-51.
27. Yadav D, Lee ES, Kim HM, Lee EY, Choi E, Chung CH. Hyperuricemia as a Potential Determinant of Metabolic Syndrome. J Lifestyle Med. 2013 Sep;3(2):98-106
28. Fang Y, Mei W, Wang C, Ren X, Hu J, Su F, Cao L, Tavengana G, Jiang M, Wu H, Wen Y. Dyslipidemia and hyperuricemia: a cross-sectional study of residents in Wuhu, China. BMC Endocr Disord. 2024 Jan 2;24(1):2.
29. Qi J, Ren X, Hou Y, Zhang Y, Zhang Y, Tan E, Wang L. Triglyceride-Glucose Index is Significantly Associated with the Risk of Hyperuricemia in Patients with Nonalcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes. 2023 May 8;16:1323-1334.
30. Mullugeta Y, Chawla R, Kebede T, Worku Y. Dyslipidemia associated with poor glycemic control in type 2 diabetes mellitus and the protective effect of metformin supplementation. Indian J Clin Biochem. 2012 Oct;27(4):363-9.
31. Gyurászová M, Gurecká R, Bábíčková J, Tóthová Ľ. Oxidative Stress in the Pathophysiology of Kidney Disease: Implications for Noninvasive Monitoring and Identification of Biomarkers. Oxid Med Cell Longev. 2020 Jan 23;2020:5478708.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Shazia Nazir
Department of Biochemistry, Govt Medical College, Srinagar, J&K, India.
Mohammad Hayat Bhat
Department of Endocrinology, Super Specialty Hospital, Srinagar & Associated Hospitals, J&K, India.
Javaid Ahmad Bhat
Department of Biochemistry, Govt Medical College, Srinagar, J&K, India.
Haamid Bashir
Department of Biochemistry, Govt Medical College, Srinagar, J&K, India
Sabhiya Majid
Department of Biochemistry, Govt Medical College, Srinagar, J&K, India